Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

817
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
817
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

105
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
105
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

74
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
74
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

96
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
96
Angina IV: Management01:26

Angina IV: Management

105
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
105
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

242
Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
242

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Management of Patients at Risk of Ischemic Stroke With Left Ventricular Systolic Dysfunction in the Absence of Intracardiac Thrombus: A Scientific Statement From the American Heart Association.

Stroke·2026
Same author

Post-Myocardial Infarction Psychological Distress: A Scientific Statement From the American Heart Association.

Circulation·2025
Same author

Correction to: 2025 AHA/ACC Clinical Performance and Quality Measures for Patients With Chronic Coronary Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Performance Measures.

Circulation. Cardiovascular quality and outcomes·2025
Same author

2025 AHA/ACC Clinical Performance and Quality Measures for Patients With Chronic Coronary Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Performance Measures.

Journal of the American College of Cardiology·2025
Same author

2025 AHA/ACC Clinical Performance and Quality Measures for Patients With Chronic Coronary Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Performance Measures.

Circulation. Cardiovascular quality and outcomes·2025
Same author

Optimizing Psychological Health Across the Perinatal Period: An Update on Maternal Cardiovascular Health: A Scientific Statement From the American Heart Association.

Journal of the American Heart Association·2025

関連する実験動画

Updated: Nov 8, 2025

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

5.5K

急性冠動脈症候群後の口服抗血小板療法: レビュー

Hassan Kamran1, Hani Jneid1,2, Waleed T Kayani1

  • 1Section of Cardiology, Department of Medicine, Baylor College of Medicine, Houston, Texas.

JAMA
|April 20, 2021
PubMed
まとめ

二重抗血小板療法 (DAPT) でアスピリンとP2Y12阻害剤を併用すると,急性冠動脈症候群 (ACS) の患者で心血管疾患が著しく減少します. 治療期間と薬剤の選択は,出血と缺血のリスクに基づいて個別化する必要があります.

さらに関連する動画

Ferric Chloride-induced Murine Thrombosis Models
10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

22.4K
Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

1.2K

関連する実験動画

Last Updated: Nov 8, 2025

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

5.5K
Ferric Chloride-induced Murine Thrombosis Models
10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

22.4K
Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

1.2K

科学分野:

  • 心臓病科
  • 薬理学について
  • 臨床医学

背景:

  • 急性冠動脈症候群 (ACS) は,年間約100万人の米国における主要な死因です.
  • アスピリンとP2Y12阻害剤を併用した二重抗血小板療法 (DAPT) は,ACS後の心血管疾患の減少に極めて重要です.

研究 の 目的:

  • ACS患者のDAPT療法と治療期間に関する現在のガイドラインと最近の証拠をレビューする.
  • 個人の出血と不血症リスクプロファイルに基づいてDAPTの調整の重要性を強調する.

主な方法:

  • 2016年のACC/AHAガイドラインの分析と,ACSにおける抗血小板治療に関する,その後のランダム化臨床試験
  • 出血リスクの階層化と患者の特徴を含む,DAPTの持続時間に影響を与える要因の評価.
  • 新しいP2Y12阻害剤 (プラスグレル,チカグレル) とクロピドグレルの有効性と安全性の比較

主要な成果:

  • DAPTの推奨期間は,低出血リスクの場合は長期間,高出血リスクの場合は短期間 (3~6ヶ月) である.
  • 高出血リスクは,特定の基準によって定義される (例えば,年齢 ≥65,低BMI,以前の出血,経口抗凝固剤の使用).
  • 新しいP2Y12阻害剤はより強力で,プラズグレルは,出血を増加させることなく,血性イベントを減らすために,ISAR- REACT-5でチカグレロールよりも優れていることを示した.

結論:

  • DAPTはACSにおける心血管疾患の減少に効果的です.
  • 最適なDAPT戦略には,患者に特有の出血および缺血のリスクを慎重に考慮する必要があります.
  • P2Y12阻害剤を投与する前にアスピリンの投与を中止すると,結果が改善することが示唆されています.